Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Major study tracks lung disease progression in over 1,400 patients

NCT ID NCT07560189

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 1,423 adults with idiopathic pulmonary fibrosis (IPF) for two years to learn how the disease progresses naturally. Researchers will track events like sudden worsening, hospital stays, and deaths. The goal is to better understand IPF patterns, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,423 people

The number who actually took part.

Started

Apr 2022

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with idiopathic pulmonary fibrosis enrolled in a longitudinal observational cohort at Assiut University between 2022 and 2026. Participants undergo standardized baseline evaluation and structured follow-up to document disease progression, acute exacerbations, hospitalization, and mortality. The cohort represents real-world clinical practice and includes patients eligible for longitudinal assessment without intervention assignment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years. * Diagnosis of idiopathic pulmonary fibrosis based on clinical and radiological assessment according to standard guidelines. * Availability of baseline clinical, functional, and radiological evaluation. * Enrollment within the Assiut University IPF Research Program. * Ability to undergo longitudinal follow-up and outcome assessment. Exclusion Criteria: * Interstitial lung disease other than idiopathic pulmonary fibrosis * Alternative diagnosis inconsistent with IPF based on clinical or radiological evaluation * Incomplete baseline data preventing cohort classification * Refusal to participate or inability to complete follow-up * End-stage disease at baseline requiring invasive mechanical ventilation or terminal care * Active malignancy or severe comorbidity expected to dominate short-term prognosis * Long-term systemic immunosuppressive therapy not aligned with standard IPF management

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis (IPF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disease Progression idiopathic pulmonary fibrosis pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic pulmonary fibrosis (IPF)

Contacts and locations

Locations

  • Faculty Of Medicine - Assiut University Hospitals - Assiut - Egypt

    Asyut, 71515, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.